Nationwide epidemiology of carbapenem resistant Klebsiella pneumoniae isolates from Greek hospitals, with regards to plazomicin and aminoglycoside resistance

BMC Infectious Diseases

Volumn 19, Issue 1, 2019, Pages

  Galani, Irene ^a,c   Nafplioti, Konstantina ^a   Adamou, Panagiota ^a   Karaiskos, Ilias ^b   Giamarellou, Helen ^b   Souli, Maria ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b HYGEIA HOSPITAL   (Greece)

^c NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Carbapenemase; Greece; K. pneumoniae; Plazomicin

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; APRAMYCIN; GENTAMICIN; NEOMYCIN; NETILMICIN; PLAZOMICIN; TOBRAMYCIN; 6'-(HYDROXYLETHYL)-1-(HABA)-SISOMICIN; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE; CARBAPENEM DERIVATIVE; CARBAPENEMASE; METHYLTRANSFERASE; RNA 16S; RRNA (ADENOSINE-O-2'-)METHYLTRANSFERASE; SISOMICIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CARBAPENEM RESISTANT KLEBSIELLA PNEUMONIAE; CONTROLLED STUDY; GENOTYPE; INFECTION CONTROL; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR EPIDEMIOLOGY; NONHUMAN; POLYMERASE CHAIN REACTION; PULSED FIELD GEL ELECTROPHORESIS; ANALOGS AND DERIVATIVES; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; DRUG EFFECT; GREECE; HOSPITAL; HUMAN; ISOLATION AND PURIFICATION; KLEBSIELLA INFECTION; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

AMIKACIN; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; CARBAPENEMS; GENTAMICINS; GREECE; HOSPITALS; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; METHYLTRANSFERASES; MICROBIAL SENSITIVITY TESTS; RNA, RIBOSOMAL, 16S; SISOMICIN;

EID: 85061605424     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-019-3801-1     Document Type: Article

References (29)

1. Tzouvelekis LS, Markogiannakis A, Psichogiou M, et al. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev. 2012;25(4):682-707. https://doi.org/10.1128/CMR.05035-11.
2. Karaiskos I, Giamarellou H. Multidrug-resistant and extensively drug-resistant gram-negative pathogens: current and emerging therapeutic approaches. Expert Opin Pharmacother. 2014;15(10):1351-70. https://doi.org/10.1517/14656566.2014.914172.
3. Karampatakis T, Antachopoulos C, Iosifidis E, Tsakris A, Roilides E. Molecular epidemiology of carbapenem-resistant Klebsiella pneumoniae in Greece. Future Microbiol. 2016;11:809-23. https://doi.org/10.2217/fmb-2016-0042.
4. Grundmann H, Glasner C, Albiger B, Aanensen DM, Tomlinson CT, Andrasević AT, et al. Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study. Lancet Infect Dis. 2017;17(2):153-63. https://doi.org/10.1016/S1473-3099(16)30257-2.
5. Galani I, Karaiskos I, Karantani I, Papoutsaki V, Maraki S, Papaioannou V, Kazila P, Tsorlini H, Charalampaki N, Toutouza M, Vagiakou M, Pappas K, Kyratsa A, Kontopoulou K, Legga O, Petinaki E, Papadogeorgaki H, Chinou E, Souli M, Giamarellou H, On Behalf Of The Study Collaborators. Epidemiology and resistance phenotypes of carbapenemase-producing Klebsiella pneumoniae in Greece, 2014-2016. Euro Surveill. 2018;23(31). https://doi.org/10.2807/1560-7917.ES.2018.23.30.1700775.
6. Leggett JE. Aminoglycosides. In: Bennett JE, Dolin R, Blaser MJ, editors. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. Philadelphia: Elsevier Saunders; 2015. p. 224-33.
7. Doi Y, Wachino JI, Arakawa Y. Aminoglycoside resistance: the emergence of acquired 16S ribosomal RNA methyltransferases. Infect Dis Clin N Am. 2016;30(2):523-37. https://doi.org/10.1016/j.idc.2016.02.011.
8. Galani I. Plazomicin: Aminoglycoside antibiotic. Drugs Futur. 2014;39(1):25-35. https://doi.org/10.1358/dof.2014.39.1.2095267.
9. CLSI. Methods for dilution antimicrobial susceptibility tests for Bacteria that grow aerobically; approved standard - tenth edition. CLSI document M07-A10. Wayne: Clinical and Laboratory Standards Institute; 2015.
10. CLSI. Performance standards for antimicrobial susceptibility testing. 28th ed. CLSI supplement M100. Wayne: Clinical and Laboratory Standards Institute; 2018.
11. NCCLS. Performance standards for antimicrobial disk and dilution susceptibility tests for Bacteria isolated from animals; informational supplement. NCCLS document M31-S1. Wayne: National Committee for Clinical Laboratory Standards; 2004.
12. European Society of Clinical Microbiology and Infectious Diseases [Internet]. Clinical breakpoints version 8.0. In European committee on antimicrobial susceptibility testing. Växjö: EUCAST; 2018. Available from: http://www.eucast.org/clinical-breakpoints/
13. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect Dis. 2012;18(3):268-81. https://doi.org/10.1111/j.1469-0691.2011.03570.x.
14. Aggen JB, Armstrong ES, Goldblum AA, Dozzo P, Linsell MS, Gliedt MJ, Hildebrandt DJ, Feeney LA, Kubo A, Matias RD, Lopez S, Gomez M, Wlasichuk KB, Diokno R, Miller GH, Moser HE. Synthesis and spectrum of the neoglycoside ACHN-490. Antimicrob Agents Chemother. 2010;54(11):4636-42. https://doi.org/10.1128/AAC.00572-10.
15. Livermore DM, Mushtaq S, Warner M, Zhang JC, Maharjan S, Doumith M, Woodford N. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J Antimicrob Chemother. 2011;66(1):48-53. https://doi.org/10.1093/jac/dkq408.
16. Almaghrabi R, Clancy CJ, Doi Y, Hao B, Chen L, Shields RK, Press EG, Iovine NM, Townsend BM, Wagener MM, Kreiswirth B, Nguyen MH. Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents. Antimicrob Agents Chemother. 2014;58(8):4443-51. https://doi.org/10.1128/AAC.00099-14.
17. Haidar G, Alkroud A, Cheng S, Churilla TM, Churilla BM, Shields RK, Doi Y, Clancy CJ, Nguyen MH. Association between the presence of aminoglycoside-modifying enzymes and in vitro activity of gentamicin, tobramycin, amikacin, and plazomicin against Klebsiella pneumoniae carbapenemase-and extended-spectrum-β-lactamase-producing Enterobacter species. Antimicrob Agents Chemother. 2016;60(9):5208-14. https://doi.org/10.1128/AAC.00869-16.
18. Zhang Y, Kashikar A, Bush K. In vitro activity of plazomicin against β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE). J Antimicrob Chemother. 2017;72(10):2792-5. https://doi.org/10.1093/jac/dkx261.
19. Martins AF, Bail L, Ito CAS, da Silva Nogueira K, Dalmolin TV, Martins AS, Rocha JLL, Serio AW, Tuon FF. Antimicrobial activity of plazomicin against Enterobacteriaceae-producing carbapenemases from 50 Brazilian medical centers. Diagn Microbiol Infect Dis. 2018;90(3):228-32. https://doi.org/10.1016/j.diagmicrobio.2017.11.004.
20. Haldorsen BC, Simonsen GS, Sundsfjord A, Samuelsen O, Norwegian Study Group on Aminoglycoside Resistance. Increased prevalence of aminoglycoside resistance in clinical isolates of Escherichia coli and Klebsiella spp. in Norway is associated with the acquisition of AAC(3)-II and AAC(6′)-Ib. Diagn Microbiol Infect Dis. 2014;78(1):66-9. https://doi.org/10.1016/j.diagmicrobio.2013.10.001.
21. López-Diaz MD, Culebras E, Rodríguez-Avial I, Rios E, Viñuela-Prieto JM, Picazo JJ, Rodríguez-Avial C. Plazomicin activity against 346 extended-Spectrum-β-lactamase/AmpC-producing Escherichia coli urinary isolates in relation to aminoglycoside-modifying enzymes. Antimicrob Agents Chemother. 2017;61(2). https://doi.org/10.1128/AAC.02454-16.
22. Ramirez MS, Nikolaidis N, Tolmasky ME. Rise and dissemination of aminoglycoside resistance: the aac(6′)-Ib paradigm. Front Microbiol. 2013;4:121. https://doi.org/10.3389/fmicb.2013.00121.
23. Giakkoupi P, Tryfinopoulou K, Kontopidou F, Tsonou P, Golegou T, Souki H, Tzouvelekis L, Miriagou V, Vatopoulos A. Emergence of NDM-producing Klebsiella pneumoniae in Greece. Diagn Microbiol Infect Dis. 2013;77(4):382-4. https://doi.org/10.1016/j.diagmicrobio.2013.09.001.
24. Voulgari E, Gartzonika C, Vrioni G, Politi L, Priavali E, Levidiotou-Stefanou S, Tsakris A. The Balkan region: NDM-1-producing Klebsiella pneumoniae ST11 clonal strain causing outbreaks in Greece. J Antimicrob Chemother. 2014;69(8):2091-7. https://doi.org/10.1093/jac/dku105.
25. NDM-1 dissemination among Enterobacteriaceae in Brazil, Nepal, Morocco, and India. Antimicrob Agents Chemother. 2015;59(12):7387-95. https://doi.org/10.1128/AAC.01458-15.
26. Papagiannitsis CC, Malli E, Florou Z, Sarrou S, Hrabak J, Mantzarlis K, Zakynthinos E, Petinaki E. Emergence of sequence type 11 Klebsiella pneumoniae coproducing NDM-1 and VIM-1 metallo-β-lactamases in a Greek hospital. Diagn Microbiol Infect Dis. 2017;87(3):295-7. https://doi.org/10.1016/j.diagmicrobio.2016.12.008.
27. Ramirez MS, Tolmasky ME. Aminoglycoside modifying enzymes. Drug Resist Updat. 2010;13(6):151-71. https://doi.org/10.1016/j.drup.2010.08.003.
28. Smith KP, Kirby JE. Evaluation of apramycin activity against carbapenem-resistant and -susceptible strains of Enterobacteriaceae. Diagn Microbiol Infect Dis. 2016;86(4):439-41. https://doi.org/10.1016/j.diagmicrobio.2016.09.002.
29. Hu Y, Liu L, Zhang X, Feng Y, Zong Z. In Vitro activity of neomycin, streptomycin, Paromomycin and Apramycin against Carbapenem-resistant Enterobacteriaceae clinical strains. Front Microbiol. 2017;8:2275. https://doi.org/10.3389/fmicb.2017.02275.